epitalon epithalon Epithalon 40mg – NewBioRx

(JCEM, 2006, PMID: 16352683) confirmed dose-dependent GH elevation in healthy adults

For example, growth factors from platelets can: We can achieve the same results by injecting PRP directly at the site of injured tissues

Its a big step forward for treating eosinophilic COPD

Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations